Research programme:.transforming growth factor beta modulators - Keros Therapeutics
Alternative Names: TGF-β modulators - Keros TherapeuticsLatest Information Update: 01 Feb 2024
Price :
$50 *
At a glance
- Originator Keros Therapeutics
- Class Obesity therapies
- Mechanism of Action Transforming growth factor beta modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Musculoskeletal disorders; Obesity; Unspecified
Most Recent Events
- 17 Jan 2024 Preclinical trials in Musculoskeletal disorders in USA (unspecified route) prior to January 2024 (Keros Therapeutics pipeline, January 2024)
- 17 Jan 2024 Preclinical trials in Obesity in USA (unspecified route) prior to January 2024 (Keros Therapeutics pipeline, January 2024)
- 17 Jan 2024 Preclinical trials in Unspecified in USA (unspecified route) prior to January 2024 (Keros Therapeutics pipeline, January 2024)